OGN
Organon & Co.NYSEHealthcare$6.36-4.87%ClosedMarket Cap: $1.66B
As of 2026-04-06
Valuation
P/E (TTM)
8.85
PEG
—
P/B
2.09
P/S
0.25
EV/EBITDA
7.54
DCF Value
$49.24
FCF Yield
25.7%
Div Yield
1.3%
Margins & Returns
Gross Margin
53.6%
Operating Margin
20.0%
Net Margin
3.0%
ROE
25.5%
ROA
1.5%
ROIC
5.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.51B | 50.4% | $235.0M | $-205.0M | $-0.79 | $0.02 |
| FY 2025 | $6.22B | 54.1% | $1.28B | $187.0M | $0.72 | $0.34 |
| Q3 2025 | $1.60B | 53.5% | $358.0M | $160.0M | $0.61 | $0.02 |
| Q2 2025 | $1.59B | 54.8% | $326.0M | $145.0M | $0.56 | $0.02 |
| Q1 2025 | $1.51B | 55.6% | $325.0M | $87.0M | $0.33 | $0.28 |
| Q4 2024 | $1.59B | 56.3% | $296.0M | $109.0M | $0.42 | $0.28 |
| FY 2024 | $6.40B | 58.0% | $1.49B | $864.0M | $3.33 | $1.12 |
| Q3 2024 | $1.58B | 58.3% | $390.0M | $359.0M | $1.38 | $0.28 |
| Q2 2024 | $1.61B | 58.4% | $386.0M | $195.0M | $0.75 | $0.28 |
| Q1 2024 | $1.62B | 59.0% | $414.0M | $201.0M | $0.78 | $0.28 |
| Q4 2023 | $1.60B | 57.3% | $312.0M | $546.0M | $2.13 | $0.28 |
| FY 2023 | $6.26B | 59.8% | $1.33B | $1.02B | $3.99 | $1.12 |